

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 August 2019 (15.08.2019)



(10) International Publication Number
WO 2019/157099 A1

(51) International Patent Classification:

A61K 31/137 (2006.01) A61K 47/10 (2017.01)
A61K 47/02 (2006.01)

(21) International Application Number:

PCT/US2019/016918

(22) International Filing Date:

06 February 2019 (06.02.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

15/890,131 06 February 2018 (06.02.2018) US
62/784,057 21 December 2018 (21.12.2018) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US 15/890,131 (CIP)
Filed on 06 February 2018 (06.02.2018)

(71) Applicants: **AEGIS THERAPEUTICS, LLC** [US/US];
11770 Bernardo Plaza Court, Suite 353, San Diego, California 92128 (US). **ARS PHARMACEUTICALS INC.** [US/US]; 8195 Run of the Knolls Ct., San Diego, California 92127 (US).

(72) Inventors: **LOWENTHAL, Richard**; 8195 Run of the Knolls Ct., San Diego, California 92127 (US). **MAGGIO, Edward T.**; 11770 Bernardo Plaza Court, Suite 353, San Diego, California 92128 (US). **BELL, Robert G.**; 8195 Run of the Knolls Ct., San Diego, California 92127 (US). **SHAH, Pratik**; 8195 Run of the Knolls Ct., San Diego, California 92127 (US).


(74) Agent: **ZUNIC, Valentin B.**; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE

Figure 4. Mean Plasma Epinephrine Concentrations with Intranasal Epinephrine Described in Example 2B.



(57) Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*